The complaint alleges that GeneDx and its top executives misled investors about the benefits of the Company's April 2025 acquisition of Fabric Genomics, an AI-driven genomic interpretation firm. Throughout the class period, the Company repeatedly told investors that Fabric would expand GeneDx's addressable market, unlock recurring software-based revenue streams, reduce costs by combining Fabric's algorithms with GeneDx's core platform, and drive growth and unprecedented scale. According to the complaint, these statements were false or misleading because the executives knew or recklessly disregarded significant problems with Fabric's viability and its ability to contribute to the Company's business. The truth emerged after market close on May 4, 2026, when GeneDx reported disappointing first-quarter 2026 results, missed revenue estimates for its exome and genome lines, slashed full-year revenue guidance from $540–$555 million to $475–$490 million, and disclosed a $31.2 million impairment write-off tied directly to Fabric, causing the stock to fall approximately 49% the following day.
Contact our attorneys for a no-cost case evaluation.